Health AI Central
Peer-Reviewed Publication
J Neurooncol2026;180(1)October 3, 2026Journal Article

Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice.

Cecile Riviere-Cazaux1, Rahul Kumar1, Julian S Rechberger1, Derrick Obiri-Yeboah1, Chao Dai2, Jie Li2, Yong Huang2, Arthur E Warrington1,3, Essa H Sharif1, Elizabeth A Palmer1, Xiaohong Wang2, Daniel H Lachance3, Sani H Kizilbash4, Michael W Ruff3, Ivan D Carabenciov3, Shannon P Fortin Ensign5,6, Gelareh Zadeh1, Bryan J Neth3,4, Ugur Sener3,4, Pan Du2, Shidong Jia2, Terry C Burns7,8
1Department of Neurological Surgery, Mayo Clinic, Rochester, MN, USA.
2Predicine, Inc., Hayward, CA, USA.
3Department of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
4Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
5Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
6Department of Cancer Biology, Mayo Clinic, Phoenix, AZ, USA.
7Department of Neurological Surgery, Mayo Clinic, Rochester, MN, USA. Burns.Terry@mayo.edu.
8Department of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. Burns.Terry@mayo.edu.
PubMed DOI

Abstract

PURPOSE: Cerebrospinal fluid (CSF) cell-free DNA (cfDNA) is increasingly used as a liquid biopsy in neuro-oncology for diagnosing lesions of uncertain etiology, distinguishing progression from pseudoprogression, and ruling out leptomeningeal disease (LMD). We assessed our institution's early experience with a new CSF cfDNA molecular profiling assay for detecting variant alleles (VA) and copy-numbe…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.